(Q38165863)

30 August 2017

Molecular basis of pharmacological therapy in Cushing's disease (English)

1 reference

30 August 2017

4

1 reference

30 August 2017

5

Annamaria Colao

1 reference

30 August 2017

6

Rosario Pivonello

1 reference

30 August 2017

Diego Ferone

1

1 reference

PubMed ID

24272603

30 August 2017

Claudia Pivonello

series ordinal

2

1 reference

PubMed ID

24272603

30 August 2017

Giovanni Vitale

series ordinal

3

1 reference

30 August 2017

23 November 2013

1 reference

30 August 2017

1 reference

30 August 2017

46

1 reference

30 August 2017

2

1 reference

30 August 2017

181-198

1 reference

https://scigraph.springernature.com/pub.10.1007/s12020-013-0098-5

30 August 2017

0 references

cites work

Treatment of adrenocorticotropin-dependent Cushing's syndrome: a consensus statement

1 reference

https://api.crossref.org/works/10.1007%2FS12020-013-0098-5

Intraoperative multiple-staged resection and tumor tissue identification using frozen sections provide the best result for the accurate localization and complete resection of tumors in Cushing's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-013-0098-5

Neurotransmitter regulation of the hypothalamic corticotropin-releasing hormone neuron

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-013-0098-5

Neuroregulation of the hypothalamus-pituitary-adrenal (HPA) axis in humans: effects of GABA-, mineralocorticoid-, and GH-Secretagogue-receptor modulation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-013-0098-5

Lack of Effect of Antiserotoninergic and/or Dopaminergic Treatment in Patients with Pituitary-Dependent Cushing's Syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-013-0098-5

Effect of an Antiserotoninergic Drug, Metergoline, on the ACTH and Cortisol Response to Insulin Hypoglycemia and Lysine-Vasopressin in Man

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-013-0098-5

Neurotransmitter modulation of corticotropin releasing factor secretion into the hypophysial-portal circulation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-013-0098-5

Cyclical Cushing's disease and its successful control under sodium valproate

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-013-0098-5

Role of the PPAR-γ system in normal and tumoral pituitary corticotropic cells and adrenal cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-013-0098-5

Functional PPAR-gamma receptor is a novel therapeutic target for ACTH-secreting pituitary adenomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-013-0098-5

Oxytocin and vasopressin agonists and antagonists as research tools and potential therapeutics

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-013-0098-5

Vasopressin receptor antagonists and their role in clinical medicine

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-013-0098-5

Drugs in the medical treatment of Cushing's syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-013-0098-5

Retinoic acid prevents experimental Cushing syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-013-0098-5

Bone morphogenetic protein-4 inhibits corticotroph tumor cells: involvement in the retinoic acid inhibitory action

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-013-0098-5

Retinoic acid as a novel medical therapy for Cushing's disease in dogs

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-013-0098-5

Potential role for retinoic acid in patients with Cushing's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-013-0098-5

Evidence that endogenous SST inhibits ACTH and ghrelin expression by independent pathways.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-013-0098-5

Native somatostatin sst2 and sst5 receptors functionally coupled to Gi/o-protein, but not to the serum response element in AtT-20 mouse tumour corticotrophs

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-013-0098-5

Somatostatin receptor subtypes 2 and 5 inhibit corticotropin-releasing hormone-stimulated adrenocorticotropin secretion from AtT-20 cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-013-0098-5

Inhibition of Adrenocorticotropin Secretion by Somatostatin in Pituitary Cells in Culture*

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-013-0098-5

Somatostatin receptor type 5 modulates somatostatin receptor type 2 regulation of adrenocorticotropin secretion.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-013-0098-5

Distinct functional properties of native somatostatin receptor subtype 5 compared with subtype 2 in the regulation of ACTH release by corticotroph tumor cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-013-0098-5

The multi-ligand somatostatin analogue SOM230 inhibits ACTH secretion by cultured human corticotroph adenomas via somatostatin receptor type 5.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-013-0098-5

Regulation of CRH-induced secretion of ACTH and corticosterone by SOM230 in rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-013-0098-5

Octreotide and the novel multireceptor ligand somatostatin receptor agonist pasireotide (SOM230) block the adrenalectomy-induced increase in mitotic activity in male rat anterior pituitary

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-013-0098-5

The role of somatostatin analogs in Cushing's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-013-0098-5

Role of somatostatin receptors in normal and tumoral pituitary corticotropic cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-013-0098-5

Unexpected activation of pituitary-adrenal axis in healthy young and elderly subjects during somatostatin infusion

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-013-0098-5

The pituitary-adrenal response to CRF-41 is unaltered by intravenous somatostatin in normal subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-013-0098-5

Effects of growth hormone release-inhibiting hormone and bromocryptine (CB 154) in states of abnormal pituitary-adrenal function

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-013-0098-5

Octreotide exerts different effects in vivo and in vitro in Cushing's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-013-0098-5

Failure of somatostatin and octreotide to acutely affect the hypothalamic-pituitary-adrenal function in patients with corticotropin hypersecretion

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-013-0098-5

Studies on the conditions determining the inhibitory effect of somatostatin on adrenocorticotropin, prolactin and thyrotropin release by cultured rat pituitary cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-013-0098-5

Differential regulation of human dopamine D2 and somatostatin receptor subtype expression by glucocorticoids in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-013-0098-5

Somatostatin-dopamine ligands in the treatment of pituitary adenomas.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-013-0098-5

Coexpression of dopamine and somatostatin receptor subtypes in corticotroph adenomas.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-013-0098-5

Differential expression of somatostatin and dopamine receptor subtype genes in adrenocorticotropin (ACTH)-secreting pituitary tumors and silent corticotroph adenomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-013-0098-5

The Effects of SOM230 on Cell Proliferation and Adrenocorticotropin Secretion in Human Corticotroph Pituitary Adenomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-013-0098-5

Somatostatin analogues stimulate p27 expression and inhibit the MAP kinase pathway in pituitary tumours.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-013-0098-5

Differential ligand-mediated pituitary somatostatin receptor subtype signaling: implications for corticotroph tumor therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-013-0098-5

Differential effects of octreotide and pasireotide on somatostatin receptor internalization and trafficking in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-013-0098-5

Somatostatin, but not somatostatin receptor subtypes 2 and 5 selective agonists, inhibits calcitonin secretion and gene expression in the human medullary thyroid carcinoma cell line, TT.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-013-0098-5

Pasireotide alone or with cabergoline and ketoconazole in Cushing's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-013-0098-5

Novel insights in dopamine receptor physiology

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-013-0098-5

Role of dopamine receptors in normal and tumoral pituitary corticotropic cells and adrenal cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-013-0098-5

Preclinical and clinical experiences with the role of dopamine receptors in the treatment of pituitary adenomas.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-013-0098-5

The clinical-molecular interface of somatostatin, dopamine and their receptors in pituitary pathophysiology

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-013-0098-5

Bromocriptine inhibits pro-opiomelanocortin mRNA and ACTH precursor secretion in small cell lung cancer cell lines

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-013-0098-5

Dopamine receptor expression and function in corticotroph pituitary tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-013-0098-5

Receptors for dopamine and somatostatin: formation of hetero-oligomers with enhanced functional activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-013-0098-5

Novel chimeric somatostatin analogs: facts and perspectives.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-013-0098-5

Somatostatin and dopamine receptor expression in lung carcinoma cells and effects of chimeric somatostatin-dopamine molecules on cell proliferation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-013-0098-5

Somatostatin and dopamine receptors as targets for medical treatment of Cushing's Syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-013-0098-5

Phase I trial of temozolomide (CCRG 81045: M&B 39831: NSC 362856)

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-013-0098-5

Chemical approaches to the discovery and development of cancer therapies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-013-0098-5

Treatment of pituitary neoplasms with temozolomide: a review.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-013-0098-5

High incidence of low O(6)-methylguanine DNA methyltransferase expression in invasive macroadenomas of Cushing's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-013-0098-5

O-6-methylguanine-DNA methyltransferase (MGMT) immunohistochemical expression in pituitary corticotroph adenomas.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-013-0098-5

Pituitary carcinomas and aggressive pituitary tumours: merits and pitfalls of temozolomide treatment.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-013-0098-5

MGMT immunoexpression predicts responsiveness of pituitary tumors to temozolomide therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-013-0098-5

Temozolomide, a novel alkylating agent with activity in the central nervous system, may improve the treatment of advanced metastatic melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-013-0098-5

Temozolomide-induced inhibition of pituitary adenoma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-013-0098-5

Vascular endothelial growth factor, its receptor KDR/Flk-1, and pituitary tumor transforming gene in pituitary tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-013-0098-5

Anti-VEGF therapy in pituitary carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-013-0098-5

The c-erbB-2/neu proto-oncogene in human pituitary tumours.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-013-0098-5

Expression and function of ErbB receptors and ligands in the pituitary

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-013-0098-5

Proliferation of the murine corticotropic tumour cell line AtT20 is affected by hypophysiotrophic hormones, growth factors and glucocorticoids

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-013-0098-5

EGFR as a therapeutic target for human, canine, and mouse ACTH-secreting pituitary adenomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-013-0098-5

Mammalian target of rapamycin inhibitors rapamycin and RAD001 (everolimus) induce anti-proliferative effects in GH-secreting pituitary tumor cells in vitro.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-013-0098-5

Effect of everolimus on cell viability in nonfunctioning pituitary adenomas.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-013-0098-5

Activation of RAF/MEK/ERK and PI3K/AKT/mTOR pathways in pituitary adenomas and their effects on downstream effectors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-013-0098-5

New targeted therapies in pituitary carcinoma resistant to temozolomide

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-013-0098-5

The somatostatin analogue octreotide confers sensitivity to rapamycin treatment on pituitary tumor cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-013-0098-5

mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-013-0098-5

Rationale for treatment and therapeutic options in Cushing's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-013-0098-5

The use of ketoconazole as an inhibitor of steroid production

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-013-0098-5

Medical treatment of Cushing's syndrome: adrenal-blocking drugs and ketaconazole

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-013-0098-5

Ketoconazole inhibits corticotropic cell function in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-013-0098-5

Use of ketoconazole in the treatment of Cushing's syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-013-0098-5

Therapy of Cushing's syndrome with steroid biosynthesis inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-013-0098-5

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-013-0098-5

Pharmacological management of Cushing's syndrome: an update

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-013-0098-5

Treatment of Cushing disease: overview and recent findings

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-013-0098-5

Medical therapy of Cushing's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-013-0098-5

Adjuvant mitotane treatment for adrenocortical carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-013-0098-5

Mitotane reduces human and mouse ACTH-secreting pituitary cell viability and function

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-013-0098-5

Therapeutic concentrations of mitotane (o,p'-DDD) inhibit thyrotroph cell viability and TSH expression and secretion in a mouse cell line model

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-013-0098-5

Treatment of Cushing's disease by O,p'DDD. Survey of 62 cases

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-013-0098-5

Sustained Remission of Cushing's Disease with Mitotane and Pituitary Irradiation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-013-0098-5

Coexpression of CYP11B2 or CYP11B1 with adrenodoxin and adrenodoxin reductase for assessing the potency and selectivity of aldosterone synthase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-013-0098-5

Aldosterone synthase inhibition with LCI699: a proof-of-concept study in patients with primary aldosteronism

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-013-0098-5

Effects of a novel aldosterone synthase inhibitor for treatment of primary hypertension: results of a randomized, double-blind, placebo- and active-controlled phase 2 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-013-0098-5

Treatment of Cushing's Syndrome with Trilostane (WIN 24,540), an Inhibitor of Adrenal Steroid Biosynthesis*

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-013-0098-5

Etomidate unmasks intraadrenal regulation of steroidogenesis and proliferation in adrenal cortical cell lines

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-013-0098-5

A novel use of etomidate for intentional adrenal suppression to control severe hypercortisolemia in childhood.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-013-0098-5

Mifepristone (RU 486) in Cushing's syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-013-0098-5

The glucocorticoid receptor and RU 486 in man.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-013-0098-5

Glucocorticoid receptor physiology

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-013-0098-5

Transcriptional interference between c-Jun and the glucocorticoid receptor: mutual inhibition of DNA binding due to direct protein-protein interaction.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-013-0098-5

Immunocytochemical analysis of hormone mediated nuclear translocation of wild type and mutant glucocorticoid receptors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-013-0098-5

Differential effects of the new glucocorticoid receptor antagonist ORG 34517 and RU486 (mifepristone) on glucocorticoid receptor nuclear translocation in the AtT20 cell line

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-013-0098-5

Differential effect of glucocorticoid receptor antagonists on glucocorticoid receptor nuclear translocation and DNA binding.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-013-0098-5

Pharmacological properties of mifepristone: toxicology and safety in animal and human studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-013-0098-5

Pituitary-adrenal response to the antiglucocorticoid action of RU 486 in Cushing's syndrome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-013-0098-5

The ectopic adrenocorticotropin syndrome: clinical features, diagnosis, management, and long-term follow-up.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-013-0098-5

Merits and pitfalls of mifepristone in Cushing's syndrome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-013-0098-5

Medical treatment of Cushing's syndrome: glucocorticoid receptor antagonists and mifepristone

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-013-0098-5

Mifepristone, a glucocorticoid receptor antagonist, produces clinical and metabolic benefits in patients with Cushing's syndrome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-013-0098-5

Cortisol, 11beta-hydroxysteroid dehydrogenases, and hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-013-0098-5

Mifepristone: is there a place in the treatment of Cushing's disease?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-013-0098-5

Clinical review: Diagnosis and management of pituitary carcinomas.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-013-0098-5

Pituitary carcinoma: a review of the literature

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-013-0098-5

Long-term survival with ACTH-secreting carcinoma of the pituitary: a case report and review of the literature

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-013-0098-5

Malignant pituitary corticotroph adenomas: report of two cases and a comprehensive review of the literature.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-013-0098-5

SOM230 (pasireotide) and temozolomide achieve sustained control of tumour progression and ACTH secretion in pituitary carcinoma with widespread metastases

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-013-0098-5

Temozolomide treatment in aggressive pituitary tumors and pituitary carcinomas: a French multicenter experience.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-013-0098-5

Long-term response of pituitary carcinoma to temozolomide. Report of two cases.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-013-0098-5

Temozolomide treatment of a pituitary carcinoma and two pituitary macroadenomas resistant to conventional therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-013-0098-5

Low O6-methylguanine-DNA methyltransferase (MGMT) expression and response to temozolomide in aggressive pituitary tumours.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-013-0098-5

Temozolomide (Temodar®) and capecitabine (Xeloda®) treatment of an aggressive corticotroph pituitary tumor.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-013-0098-5

Successful long-term treatment of Cushing disease with mifepristone (RU486).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-013-0098-5

Use of intravenous etomidate to control acute psychosis induced by the hypercortisolaemia in severe paediatric Cushing's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-013-0098-5

Sodium valproate and cyproheptadine may independently induce a remission in the same patient with Cushing's disease

21 January 2018

1 reference

12 December 2020

1 reference

12 December 2020

Effect of the serotonin antagonists ritanserin and ketanserin in Cushing's disease

1 reference

12 December 2020

Proliferation Markers and EGF in ACTH-Secreting Adenomas and Carcinomas of the Pituitary

1 reference

12 December 2020

Pasireotide, a multiple somatostatin receptor subtypes ligand, reduces cell viability in non-functioning pituitary adenomas by inhibiting vascular endothelial growth factor secretion

1 reference

12 December 2020

Induction of apoptosis in murine ACTH-secreting pituitary adenoma cells by bromocriptine

1 reference

12 December 2020

Ketoconazole inhibits oxidative modification of low density lipoprotein

1 reference

12 December 2020

Effect of Sandostatin on CRF-Stimulated Secretion of ACTH, β-Lipotropin and β-Endorphin

1 reference

12 December 2020

Mitotane, metyrapone, and ketoconazole combination therapy as an alternative to rescue adrenalectomy for severe ACTH-dependent Cushing's syndrome

1 reference

12 December 2020

Absence of dopaminergic control on melanotrophs leads to Cushing's-like syndrome in mice

1 reference

12 December 2020

Medical management of Cushing disease

1 reference

12 December 2020

Effects of somatostatin and bromocryptine on the plasma ACTH level in bilaterally adrenalectomized patients with Cushing's disease

1 reference

12 December 2020

Cholesterol metabolism during ketoconazole treatment in man

1 reference

12 December 2020

Somatostatin and dopamine-somatostatin multiple ligands directed towards somatostatin and dopamine receptors in pituitary adenomas

1 reference

12 December 2020

The involvement of serotonin in regulation of pituitary-adrenocortical function.

1 reference

12 December 2020

MGMT immunohistochemical expression and promoter methylation in human glioblastoma

1 reference

12 December 2020

Stimulatory Effects of Gamma-Aminohydroxybutyric Acid (GABOB) on Growth Hormone, Prolactin and Cortisol Release in Man

1 reference

12 December 2020

Significant response to pasireotide (SOM230) in the treatment of a patient with persistent, refractory Cushing's disease

1 reference

12 December 2020

Temozolomide: a novel treatment for pituitary carcinoma

1 reference

12 December 2020

A 12-Month Phase 3 Study of Pasireotide in Cushing's Disease

1 reference

12 December 2020

Experience with trilostane in the treatment of Cushing's syndrome

1 reference

12 December 2020

Expression of somatostatin receptors on human pituitary adenomas in vivo and ex vivo

1 reference

12 December 2020

Ketoconazole therapy in Cushing's disease

1 reference

12 December 2020

Effects of Cyproheptadine, Reserpine, and Synthetic Corticotropin-Releasing Factor on Pituitary Glands from Patients with Cushing's Disease*

1 reference

12 December 2020

Steroid antagonists and receptor-associated proteins

1 reference

12 December 2020

Immunohistochemical analysis of tumor angiogenic factors in human pituitary adenomas

1 reference

12 December 2020

Failure of long-term therapy with sodium valproate in Cushing's disease

1 reference

12 December 2020

Effects of rosiglitazone--peroxisome proliferators-activated receptor gamma (PPARgamma) agonist on cell viability of human pituitary adenomas in vitro

1 reference

12 December 2020

11 beta-Hydroxysteroid dehydrogenase activity in Cushing's syndrome: explaining the mineralocorticoid excess state of the ectopic adrenocorticotropin syndrome

1 reference

12 December 2020

Advances in medical therapies for Cushing's syndrome.

1 reference

12 December 2020

Growth factors and human pituitary adenomas

1 reference

12 December 2020

Localization of Epidermal Growth Factor (EGF) and Epidermal Growth Factor Receptor (EGFr) in Human Pituitary Adenomas and Nontumorous Pituitaries: An Immunocytochemical Study

1 reference

12 December 2020

Combination therapy for Cushing's disease: effectiveness of two schedules of treatment: should we start with cabergoline or ketoconazole?

1 reference

12 December 2020

Role of MGMT in tumor development, progression, diagnosis, treatment and prognosis

1 reference

12 December 2020

Short and long-term responses to metyrapone in the medical management of 91 patients with Cushing's syndrome

1 reference

12 December 2020

Cyproheptadine treatment in Cushing's disease

1 reference

12 December 2020

The combined use of sodium valproate and metyrapone in the treatment of Cushing's syndrome

1 reference

12 December 2020

Cyproheptadine-Induced Remission of Cushing's Disease

1 reference

12 December 2020

No effect of the PPAR-gamma agonist rosiglitazone on ACTH or cortisol secretion in Nelson's syndrome and Cushing's disease in vitro and in vivo.

1 reference

12 December 2020

Response of pituitary-adrenal axis to corticotrophin releasing hormone in patients with Cushing's disease before and after ketoconazole treatment

1 reference

12 December 2020

Somatostatin: A potent inhibitor of ACTH-Hypersecretion in adrenal insufficiency

1 reference

12 December 2020

Pituitary-targeted medical therapy of Cushing's disease

1 reference

12 December 2020

The role of cytotoxic chemotherapy in the management of aggressive and malignant pituitary tumors

1 reference

12 December 2020

Successful long-term treatment of refractory Cushing's disease with high-dose mifepristone (RU 486).

1 reference

12 December 2020

Medical management of Cushing disease

1 reference

12 December 2020

10.1007/S12020-013-0098-5

Identifiers

DOI

1 reference

30 August 2017

1 reference

PubMed ID

24272603